| 177.27 Net Asset Value | -0.05% 1 Day | +61.17% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 0.81% Expense Ratio | High Morningstar Risk Rating™ |
| 1 month | +3.70% | 3 years | +39.76% | |
| 3 months | +7.78% | 5 years | +28.68% | |
| 1 year | +60.72% | Since inception | +13.84% |
| FBIOX | Category | |
|---|---|---|
| Performance 5-yr return | +28.68% | +14.97% |
| Expense ratio | 0.81% | 1.49% |
| Risk 5 year sharpe ratio | 1.20 | 1.17 |
| Net assets | $7.4B | $2.1B |
| Average market cap | $11.7B | $24.0B |
| Average P/E | 29.0 | 25.7 |
| Portfolio turnover | 42% | 42% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Fidelity Investments |
| Fund manager & tenure | Rajiv Kaul / 8 Years |
| Minimal initial investment | $2,500.00 |
| Minimum IRA investment | $200.00 |
| U.S. stock | 98.64% |
| International stock | 1.13% |
| Fixed income | 0.11% |
| Cash | 0.10% |
| Other | 0.01% |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| GILD Gilead Sciences Inc | 14.56% |
| AMGN Amgen Inc | 12.54% |
| CELG Celgene Corporation | 7.68% |
| BIIB Biogen Idec Inc | 6.62% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.20% |
| ALXN Alexion Pharmaceuticals, Inc. | 3.79% |
| VRTX Vertex Pharmaceuticals | 2.92% |
| PCYC Pharmacyclics, Inc. | 2.67% |
| AEGR Aegerion Pharmaceuticals, Inc. | 2.56% |
| BMRN Biomarin Pharmaceutical, Inc. | 1.94% |
.
